Epidemiological and molecular studies suggest that Alzheimer’s disease (AD) has multiple etiologies including genetic mutations, genetic variations affecting susceptibility and environmental factors. These aspects can promote the formation and accumulation of insoluble amyloid-β and hyperphosphorylated tau. Since the disease is multifactorial and clinical diagnosis is highly exclusive, the need for a sensitive, specific and reliable biomarker is crucial.
The concept of a biomarker implies sensitivity and specificity relative to the condition being considered. For clinical practice, AD diagnosis has been based on adherence to clinical criteria such as the NINCDS/ADRDA and DSM-IV. A more recent set of diagnostic criteria proposed incorporates imaging findings into the diagnosis of AD.
In this article, we consider the most studied candidates or group of candidates for AD biomarkers, including pathological processes and proteins (amyloid-β, tau, oxidative stress, mitochondrial/metabolic changes and cell-cycle processes), or autoantibodies thereto, as well as genetic factors.
Biomarkers in Alzheimer’s disease: past, present and future
Katarzyna Gustaw-Rothenberg1,2, Alan Lerner1, David J Bonda3, Hyoung-gon Lee3, Xiongwei Zhu3, George Perry3,4 & Mark A Smith3††Author for correspondence
Biomarkers in Medicine
February 2010, Vol. 4, No. 1, Pages 15-26
No comments:
Post a Comment